Rubius Therapeutics (RUBY) Tops Q4 EPS by 4c

Rubius Therapeutics (NASDAQ: RUBY) reported Q4 EPS of ($0.56), $0.04 better than the analyst estimate of ($0.60).

“Over the past two years, we have generated exciting oncology preclinical data, demonstrating the ability of our Red Cell Therapeutics to both broadly activate the immune system, and induce tumor-specific responses by activating and expanding antigen-specific T cells with our artificial antigen-presenting cells. By focusing on the development of our oncology and autoimmune pipeline, we believe we will have the greatest opportunity to bring life-saving therapies to patients, enhance shareholder value and extend our cash runway into 2022,” said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. “With our internal cGMP manufacturing established, we are well positioned to advance this entirely new class of allogeneic cellular medicines.”

For earnings history and earnings-related data on Rubius Therapeutics (RUBY) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Sky Quarry names Heidi Bowman as CFO
• UBS says bull market has further to run